To evaluate the impact of Chidamide-mediated increase in CD22 site density on in vivo CAR functionality, a NAMALWA-xenograft mice model was constructed and the peripheral blood of mice was detected in day 10 to confirm there being tumor cells in blood. Here, CD22 is linked to neoplasm.